Clinical trial
A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
NCT04732416 is registered in ClinicalTrials.gov with Hanmi Pharmaceutical Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- May 5, 2022
- Completion date
- May 31, 2027
- Enrollment
- 17 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.